• Recognized by Conquer Cancer®, the ASCO® Foundation, and the 2024 ASCO® Breakthrough Program Committee, Prestigious Award Recognizes Top Scoring Study Abstracts

Yokohama, Japan and El Segundo, California – Treatment Technologies & Insights (TTI), a digital health insights and real-world data company and developer of the #1 rated ePRO app for Oncology, Wave Health, announced today it has been named a 2024 ASCO Breakthrough Abstract Award winner in recognition of their 8-clinic PRO-WAVE1 study conducted in Spain. Additionally, the study abstract, “PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform,” has been invited for poster presentation at the global ASCO meeting, taking place August 8-10 in Japan.

Given by Conquer Cancer, the ASCO Foundation, along with the 2024 ASCO Breakthrough Conference program committee, the award recognizes valuable research in clinical cancer treatment and technology innovations in cancer care. The award distinguishes the highest-scoring abstracts submitted for their global conference.

In the PRO-WAVE1 study, patients engaged with the Wave Health App over a 13-week period. Patients used the app during treatment to complete a series of validated ePRO questionnaires, as well as a Weekly Symptom Review (WSR) assessing 16 Prostate cancer-specific symptoms, including the severity and/or frequency of each symptom.  A report summary of the patients’ WSR was generated for care team to view in Wave Connect, a web-based platform – specifically for care team members to conduct weekly check-ins on patients, including verifying patient completion, evaluating report content, indicating plans for follow up with each patient, and rating their perceived value of the platform. 

In addition to a rare high 93% patient compliance rate over the course of the study, 98% of the participating HCPs indicated the Wave Health Platform was “useful” as part of patient care and treatment.  Additionally, after completing the study, 78% of the participating patients also responded to an “optional” feedback survey regarding their experience using Wave Health during treatment. Those patients conveyed remarkable experiences, including: 90% reporting being satisfied with the app to track their activities and keep their medical team informed; and 95% describing the information provided by Wave Health as “useful.”

Moreover, profile information collected as part of the study revealed a significant portion of study participants were aged 70 years or older (48%), with a maximum educational background of high school or below (52%), and during the screening process, roughly three in 10 participants (29%) reported low confidence in their ability to use app technologies.

TTI CEO Matt Lashey said, “We are honored to be included in such prestigious company in recognition of innovation to improve cancer care. The benefits of ePROs are well established, but they are not easy to operationalize.  To ensure compliance, ePRO solutions must be user-friendly and provide value – to both patients and care teams.  Wave Health does exactly that.”

Hospital participants in the PRO-WAVE1 study included: Hospital Universitario Marques de Valdecilla; Complejo Hospitalario de Navarra; Oncológico de Donostia; Fundació Puigvert Barcelona; Hospital Universitario La Paz; Hospital Universitario Virgen del Rocío; Hospital de la Sta. Creu i Sant Pau; and Hospital Universitarios Cruces.

The full study abstract (#192 / Poster board #K10) is available here.

ASCO Breakthrough Conference

Endorsed by the Japan Ministry of Health, Labor and Welfare, the ASCO Breakthrough Conference is offered in collaboration with co-host societies and regional collaborators, to connect practicing clinicians, oncology thought leaders, med-tech pioneers, and research trailblazers to spark new conversations and partnerships that transcend disciplines and nations.  For more information about the award, please visit: Conquer Cancer, and for more information about the conference: https://conferences.asco.org/breakthrough/program.

Wave Health

Wave Health is comprised of a leading patient app, analytics engine, and HCP Portal that takes in a diverse and unique data set to supplement clinical data with critical context and generates actionable insights to improve health and reduce costs. 

Born from a personal cancer experience, TTI built the Wave Health Platform to transform the management and understanding of chronic conditions – outside clinical settings, and is now being used by large pharma, ACOs, and government health agencies around the world to support decentralized clinical trials (DCTs), active oncology surveillance programs, enhance patient engagement, and improve adherence.  For more information, please visit www.wavehealth.app.

• Selected for oral abstract presentation at the 2024 Oncology Nursing Society (ONS) Congress, promoting excellence in oncology nursing and the transformation of cancer care

• Key performance metrics far surpass feasibility requirements for engaging these at-risk patients outside the clinical setting to minimize delays in symptom reporting

• Interim analysis of study endpoints showcases new opportunities to positively impact the critical timeliness and efficiency of clinician assessments and treatment decisions

---

Washington, D.C. – Treatment Technologies & Insights (TTI), parent company of Wave Health, and the Wilmot Cancer Institute at the University of Rochester Medical Center announced interim results of a joint study: “Use of a Symptoms Tracking Mobile Health Application by Adult Recipients of Allogeneic Stem Cell Transplantation (SCT) to Self-Monitor for Chronic Graft-versus-host Disease (cGVHD).”

Accepted for presentation at ONS Congress, the feasibility study aimed to determine if a customized version of the Wave Health mobile health app was feasible in and usable for self-monitoring and symptom reporting by SCT recipients at risk for cGVHD. A common post-SCT complication, cGVHD requires long-term symptom monitoring and threatens post-SCT survival and quality of life. The study emphasized consistent and intentional self-monitoring for early signs and symptoms of cGVHD, which can present unpredictably and vary in severity. This is important given the time gap between routine clinic follow ups in clinician assessments.

Fifteen study patients engaged with Wave Health over four weeks after a post-baseline clinic visit to track daily activities, mood and symptoms. In addition to onboarding and feedback surveys, patients completed four weekly symptom reviews over a period of one month. The app uses the NCI PRO-CTCAE 1.0 symptom severity 0-5 Likert scale where a 5 is “Very Severe.” The modified Wave Health app included common GVHD symptoms informed by the Lee Symptom Scale. Relevant symptom management content, and access to information about GVHD were also offered within the app.

Interim study results highlighted:

• Feasibility – 88% of subjects used the app at least once a week, far surpassing the 50% benchmark. Further, 80% were active in the app all four weeks, and on average used the app three days per week.
• Usability – 89% of subjects highly rated the app usability, including ease of use, helpfulness, relevance, and overall satisfaction, again surpassing the 50% study benchmark. 

Wilmot’s Department of Nursing study principal investigator, Dr. Jamie Oliva said, “GVHD symptom onset is often difficult to know, subtle symptoms can be missed, and determining treatment response is challenging.  These study findings showcase the opportunity to improve treatment response and guide crucial next steps in thinking about intervention opportunities.” 

Co-investigator and Wilmot Chief Nursing Officer, Dr. Rhonda (KC) Knapp Clevenger added, “Patient engagement and education with specific symptom monitoring between scheduled clinic visits – captured at onset and in changes of severity level – offers tremendous objective data to aid clinical assessment.  We look forward to continuing work in this area.”

TTI CEO Matt Lashey shared: “These results build on research we started at the Fred Hutchinson Cancer Center at the University of Washington centered on melanoma and kidney cancer patients, and most recently in a multi-center trial in Spain centered on prostate cancer patients.  Wave Health is unparalleled in its experience to deliver impactful real-world data – to impact current protocols as well as longitudinal intelligence.  To get this actionable data, you must first have the patient compliance, acceptance, retention, and satisfaction.  Wave Health uniquely delivers all of these and has demonstrated similar HCP satisfaction and perceived impact.”

---

WAVE HEALTH

Rated the #1 highest quality mHealth application to track electronic patient-reported outcomes (ePROs) for oncology patients, TTI’s full Wave Health platform also includes an HCP Portal, Wave Connect, and unique analytics engine.  Recent results from another 8-center research study using the full tech platform were accepted for poster presentation at the 2024 ASCO GU conference – showcasing a rare 93% patient compliance and 98% HCP perceived usefulness.

The Wave Health technology enables patients to not only track a holistic treatment journey, but also elevate their health literacy through access to validated patient content as well as personal and global insights driven by backend analytics.  Correspondingly, care and research teams can track and triage evolving symptoms – enabling intervention opportunities to impact patient quality of life and care costs.